![]() ![]() Psybio is creating biosynthetic psilocybin and DMT to treat a course of mental health issues.Their psilocybin formulations target mental illness indications: mood disorders (such as depression, anxiety and bi-polar disorder) and eating disorders (such as bulimia and anorexia nervosa). Psilocin Pharma partnered with the University of Wisconsin Madison and North Carolina State University to develop six natural and synthetic psilocybin formulas in the following forms: capsules, sublingual sprays, gel gaps, effervesce tablets, and breath strips.Cybin is a drug discovery company that is currently conducting a phase IIA and phase IIB clinical trial to evaluate their proprietary, sublingual psilocybin compound for the treatment of Major Depressive Disorder (MDD).In addition to conducting their own pre-clinical and clinical research to evaluate psilocybin’s efficacy for depression and anxiety, Usona provides other academic researchers with psilocybin compounds for investigational purposes. ![]() Their phase IIB clinical trial investigates psilocybin’s optimal dose, as well as its safety and efficacy profile. Compass’ psilocybin program for treatment-resistant depression was approved as an FDA Breakthrough therapy in 2018. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |